DMH1 (1206711-16-1) Description:
DMH-1 is a selective inhibitor of ACTR-I, the bone morphogenic protein (BMP) ALK2 receptor. This compound has an IC50 = 108 nM and displayes no detectable inhibition of AMPK, ALK5, KDR (VEGFR-2) or PDGFRβ receptors. DMH-1 blocks phosphorylation of Smads 1, 5, and 8 in HEK293 cells induced by BMP4.
Bone morphogenetic proteins (BMP) are secreted signaling proteins, many of which are involved in various developmental processes, in addition to bone formation.DMH1 is an analog of the non-selective BMP receptor inhibitor dorsomorphin that potently inhibits the kinase activity of activin receptor-like kinase 2 (ALK2; IC50 = 13-108 nM).It is much less effective at ALK4, ALK5, AMPK, KDR (VEGFR2) or PDGFRβ, although it inhibits ALK1 and ALK3 at nanomolar concentrations.DMH1 is effective in vivo, as it disrupts dorsoventral development in zebrafish.It also affects stem cell development, increasing cardiomyocyte progenitors and promoting neurogenesis. DMH1 inhibits the growth of lung cancer cells, reducing tumor growth in a xenograft mouse model.
DMH1 (1206711-16-1) Specifications:
|Synonyms||DMH 1; DMH-1; BMP Inhibitor II
DorsoMorphin Homolog 1
|Molecular Weight||380.451 g/mol|
|Monoisotopic Mass||380.164 g/mol|
|Color||light yellow to orange|
|Solubility||Soluble in DMSO|
|Storage Temp.||0 – 4 C for short term (days to weeks), or -20 C for long term (months).|
|Shelf life||>2 years if stored properly|
|Handling||Protect from air and light|
|Application||A selective inhibitor of the bone morphogenic protein (BMP) ALK2 receptor; ALK2 inhibitor|